FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4363673937> ?p ?o ?g. }

• W4363673937 endingPage "000" @default.
• W4363673937 startingPage "000" @default.
• W4363673937 abstract "There is a lack of data supporting the notion that antiviral treatments can benefit children with chronic hepatitis B (CHB) having high viremia and normal or mildly elevated serum alanine aminotransferase (ALT) levels. We aimed to analyze the efficacy of antiviral treatments in children with CHB and explore the factors associated with functional cure.Forty-eight children with CHB having high viremia and normal or mildly elevated serum ALT levels were screened in this real-world study. Thirty-two children received either interferon-alpha (IFN-α) monotherapy, IFN-α therapy with a nucleoside analog (NA) add-on, or IFN-α and NA combination therapy. The 16 children in the control group did not receive antiviral treatment. All 48 children were available for follow-up assessments for the entire 36-month study period. We identified a functional cure with respect to hepatitis B virus (HBV) DNA loss, loss /seroconversion of circulating hepatitis B e antigen (HBeAg), and loss of hepatitis B surface antigen (HBsAg) with or without seroconversion. Cox regression analysis was employed to evaluate the factors that may have influenced the functional cure.After 36 months, the cumulative functional cure rate was 56.25% (18/32) in the treated group and 0% (0/16) in the control group (p<0.001). In the treated group, the serum HBV DNA levels declined rapidly at the end of a 6-month visit and the cured children achieved a loss rate of 100% (18/18) within 16 months of beginning treatment, compared with 64.29% (9/14) of the uncured children (p<0.001). The rates of HBeAg seroconversion were significantly higher among the cured children than among the uncured children (p<0.001). All 16 children in the control group maintained high levels of serum HBV DNA and were positive for both serum HBeAg and HBsAg during the entire 36 months of the study period. Functional cure was associated with younger ages (1-6 vs. 7-14 years, p=0.013), CD8+ T lymphocyte counts (p=0.013), and B lymphocyte counts (p=0.003). No serious adverse events were observed.Antiviral treatment achieved a functional cure of CHB in a high proportion of children having high-level viremia and normal or mildly elevated ALT levels. Younger age and high peripheral lymphocyte counts were associated with this functional cure." @default.
• W4363673937 created "2023-04-11" @default.
• W4363673937 creator A5001221203 @default.
• W4363673937 creator A5012677271 @default.
• W4363673937 creator A5016593247 @default.
• W4363673937 creator A5025080382 @default.
• W4363673937 creator A5026303574 @default.
• W4363673937 creator A5033461362 @default.
• W4363673937 creator A5036104967 @default.
• W4363673937 creator A5036683877 @default.
• W4363673937 creator A5041395771 @default.
• W4363673937 creator A5058662188 @default.
• W4363673937 creator A5064616332 @default.
• W4363673937 creator A5071432259 @default.
• W4363673937 creator A5088441537 @default.
• W4363673937 creator A5089966579 @default.
• W4363673937 date "2023-04-10" @default.
• W4363673937 modified "2023-09-25" @default.
• W4363673937 title "Functional Cure of Chronic Hepatitis B with Antiviral Treatment in Children having High-level Viremia and Normal or Mildly Elevated Serum Aminotransferase" @default.
• W4363673937 cites W1574141134 @default.
• W4363673937 cites W1919657788 @default.
• W4363673937 cites W1996263738 @default.
• W4363673937 cites W2025132168 @default.
• W4363673937 cites W2041824372 @default.
• W4363673937 cites W2047986664 @default.
• W4363673937 cites W2052217197 @default.
• W4363673937 cites W2065939809 @default.
• W4363673937 cites W2090499699 @default.
• W4363673937 cites W2111278668 @default.
• W4363673937 cites W2122899893 @default.
• W4363673937 cites W2154527433 @default.
• W4363673937 cites W2174723704 @default.
• W4363673937 cites W2494120090 @default.
• W4363673937 cites W2605785536 @default.
• W4363673937 cites W2766366395 @default.
• W4363673937 cites W2790022403 @default.
• W4363673937 cites W2791839818 @default.
• W4363673937 cites W2885140751 @default.
• W4363673937 cites W2896700797 @default.
• W4363673937 cites W2905371854 @default.
• W4363673937 cites W2986158011 @default.
• W4363673937 cites W3025875791 @default.
• W4363673937 cites W3040928076 @default.
• W4363673937 cites W3104579748 @default.
• W4363673937 cites W3137053114 @default.
• W4363673937 cites W3140077821 @default.
• W4363673937 cites W3182923132 @default.
• W4363673937 cites W3203155522 @default.
• W4363673937 cites W3209223405 @default.
• W4363673937 cites W3214182824 @default.
• W4363673937 cites W3216045681 @default.
• W4363673937 cites W4200217608 @default.
• W4363673937 cites W4206318130 @default.
• W4363673937 cites W4213111580 @default.
• W4363673937 cites W4300661928 @default.
• W4363673937 cites W4307939648 @default.
• W4363673937 doi "https://doi.org/10.14218/jcth.2023.00014" @default.
• W4363673937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37577220" @default.
• W4363673937 hasPublicationYear "2023" @default.
• W4363673937 type Work @default.
• W4363673937 citedByCount "0" @default.
• W4363673937 crossrefType "journal-article" @default.
• W4363673937 hasAuthorship W4363673937A5001221203 @default.
• W4363673937 hasAuthorship W4363673937A5012677271 @default.
• W4363673937 hasAuthorship W4363673937A5016593247 @default.
• W4363673937 hasAuthorship W4363673937A5025080382 @default.
• W4363673937 hasAuthorship W4363673937A5026303574 @default.
• W4363673937 hasAuthorship W4363673937A5033461362 @default.
• W4363673937 hasAuthorship W4363673937A5036104967 @default.
• W4363673937 hasAuthorship W4363673937A5036683877 @default.
• W4363673937 hasAuthorship W4363673937A5041395771 @default.
• W4363673937 hasAuthorship W4363673937A5058662188 @default.
• W4363673937 hasAuthorship W4363673937A5064616332 @default.
• W4363673937 hasAuthorship W4363673937A5071432259 @default.
• W4363673937 hasAuthorship W4363673937A5088441537 @default.
• W4363673937 hasAuthorship W4363673937A5089966579 @default.
• W4363673937 hasBestOaLocation W43636739371 @default.
• W4363673937 hasConcept C126322002 @default.
• W4363673937 hasConcept C185592680 @default.
• W4363673937 hasConcept C203014093 @default.
• W4363673937 hasConcept C2522874641 @default.
• W4363673937 hasConcept C2775940106 @default.
• W4363673937 hasConcept C2776185481 @default.
• W4363673937 hasConcept C2776543447 @default.
• W4363673937 hasConcept C2777333352 @default.
• W4363673937 hasConcept C2777382497 @default.
• W4363673937 hasConcept C2777410769 @default.
• W4363673937 hasConcept C2777451964 @default.
• W4363673937 hasConcept C2778606649 @default.
• W4363673937 hasConcept C2780593183 @default.
• W4363673937 hasConcept C71240020 @default.
• W4363673937 hasConcept C71924100 @default.
• W4363673937 hasConcept C90924648 @default.
• W4363673937 hasConceptScore W4363673937C126322002 @default.
• W4363673937 hasConceptScore W4363673937C185592680 @default.
• W4363673937 hasConceptScore W4363673937C203014093 @default.
• W4363673937 hasConceptScore W4363673937C2522874641 @default.
• W4363673937 hasConceptScore W4363673937C2775940106 @default.

• next